Limits...
Effects of Continuing Adjuvant S-1 for 1 Year on the Prognosis of Gastric Cancer Patients: Results from a Prospective Single Center Study.

Eun H, Hur H, Byun CS, Son SY, Han SU, Cho YK - J Gastric Cancer (2015)

Bottom Line: Patients with continuation of S-1 for 1 year had significantly increased rates of disease-free survival (P<0.001) and overall survival (P=0.001) relative to the patients who discontinued S-1 during year 1.Excluding patients who discontinued S-1 due to cancer progression (n=7), adjuvant treatment with S-1 still demonstrated a significant difference in the disease-free survival rate between the patients who continued treatment and those who discontinued it (P=0.020).S-1 adjuvant treatment should be continued for 1 year if possible through the proper management of toxicities.

View Article: PubMed Central - PubMed

Affiliation: Division of Gastrointestinal Surgery, Department of Surgery, Ajou University School of Medicine, Suwon, Korea.

ABSTRACT

Purpose: Although several clinical trials have proven the efficacy of adjuvant S-1 treatment in gastric cancers, it is still unclear which patients receive the most benefit. In this study, we prospectively recruited patients with locally advanced gastric cancer who had undergone curative resection followed by adjuvant S-1 administration to investigate which factors affect the outcomes.

Materials and methods: Between July 2010 and October 2011, we enrolled 49 patients who underwent curative resection for stage II or III gastric cancer and who subsequently received adjuvant S-1 treatment for 1 year.

Results: Twenty-nine patients (59.2%) continued S-1 treatment for 1 year, and 12 patients (24.5%) experienced recurrent disease during the follow-up period. Patients with continuation of S-1 for 1 year had significantly increased rates of disease-free survival (P<0.001) and overall survival (P=0.001) relative to the patients who discontinued S-1 during year 1. Multivariate analysis indicated poor outcomes for patients with stage III disease and those who discontinued S-1 treatment. Excluding patients who discontinued S-1 due to cancer progression (n=7), adjuvant treatment with S-1 still demonstrated a significant difference in the disease-free survival rate between the patients who continued treatment and those who discontinued it (P=0.020).

Conclusions: S-1 is tolerated as adjuvant treatment in gastric cancer patients. However, discontinuing S-1 treatment may be an unfavorable factor in the prevention of recurrence. S-1 adjuvant treatment should be continued for 1 year if possible through the proper management of toxicities.

No MeSH data available.


Related in: MedlinePlus

Survival difference according to the continuation of adjuvant S-1 treatment.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4496437&req=5

Figure 1: Survival difference according to the continuation of adjuvant S-1 treatment.

Mentions: Additionally, we analyzed the disease-free or overall survival rates of 42 patients after the exclusion of 7 patients who received incomplete S-1 treatment due to recurrence, in order to remove bias. Of the 42 patients, 13 patients with non-completion of S-1 still demonstrated a worsening of the disease-free survival rate when compared to patients with completion of S-1 treatment (Fig. 1).


Effects of Continuing Adjuvant S-1 for 1 Year on the Prognosis of Gastric Cancer Patients: Results from a Prospective Single Center Study.

Eun H, Hur H, Byun CS, Son SY, Han SU, Cho YK - J Gastric Cancer (2015)

Survival difference according to the continuation of adjuvant S-1 treatment.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4496437&req=5

Figure 1: Survival difference according to the continuation of adjuvant S-1 treatment.
Mentions: Additionally, we analyzed the disease-free or overall survival rates of 42 patients after the exclusion of 7 patients who received incomplete S-1 treatment due to recurrence, in order to remove bias. Of the 42 patients, 13 patients with non-completion of S-1 still demonstrated a worsening of the disease-free survival rate when compared to patients with completion of S-1 treatment (Fig. 1).

Bottom Line: Patients with continuation of S-1 for 1 year had significantly increased rates of disease-free survival (P<0.001) and overall survival (P=0.001) relative to the patients who discontinued S-1 during year 1.Excluding patients who discontinued S-1 due to cancer progression (n=7), adjuvant treatment with S-1 still demonstrated a significant difference in the disease-free survival rate between the patients who continued treatment and those who discontinued it (P=0.020).S-1 adjuvant treatment should be continued for 1 year if possible through the proper management of toxicities.

View Article: PubMed Central - PubMed

Affiliation: Division of Gastrointestinal Surgery, Department of Surgery, Ajou University School of Medicine, Suwon, Korea.

ABSTRACT

Purpose: Although several clinical trials have proven the efficacy of adjuvant S-1 treatment in gastric cancers, it is still unclear which patients receive the most benefit. In this study, we prospectively recruited patients with locally advanced gastric cancer who had undergone curative resection followed by adjuvant S-1 administration to investigate which factors affect the outcomes.

Materials and methods: Between July 2010 and October 2011, we enrolled 49 patients who underwent curative resection for stage II or III gastric cancer and who subsequently received adjuvant S-1 treatment for 1 year.

Results: Twenty-nine patients (59.2%) continued S-1 treatment for 1 year, and 12 patients (24.5%) experienced recurrent disease during the follow-up period. Patients with continuation of S-1 for 1 year had significantly increased rates of disease-free survival (P<0.001) and overall survival (P=0.001) relative to the patients who discontinued S-1 during year 1. Multivariate analysis indicated poor outcomes for patients with stage III disease and those who discontinued S-1 treatment. Excluding patients who discontinued S-1 due to cancer progression (n=7), adjuvant treatment with S-1 still demonstrated a significant difference in the disease-free survival rate between the patients who continued treatment and those who discontinued it (P=0.020).

Conclusions: S-1 is tolerated as adjuvant treatment in gastric cancer patients. However, discontinuing S-1 treatment may be an unfavorable factor in the prevention of recurrence. S-1 adjuvant treatment should be continued for 1 year if possible through the proper management of toxicities.

No MeSH data available.


Related in: MedlinePlus